Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV-2 | 46 | 2023 | 156 | 5.950 |
Why?
|
Nigeria | 76 | 2024 | 770 | 5.890 |
Why?
|
HIV Infections | 123 | 2024 | 17351 | 5.370 |
Why?
|
HIV-1 | 77 | 2023 | 6863 | 4.270 |
Why?
|
Anti-HIV Agents | 33 | 2024 | 4527 | 3.560 |
Why?
|
Viral Load | 43 | 2024 | 3332 | 3.110 |
Why?
|
Drug Resistance, Viral | 15 | 2020 | 862 | 2.460 |
Why?
|
Dengue Virus | 5 | 2024 | 201 | 2.080 |
Why?
|
Dengue | 6 | 2024 | 254 | 2.060 |
Why?
|
Antiretroviral Therapy, Highly Active | 20 | 2019 | 1897 | 2.040 |
Why?
|
Anti-Retroviral Agents | 14 | 2019 | 1784 | 1.850 |
Why?
|
Pregnancy Complications, Infectious | 12 | 2024 | 2151 | 1.710 |
Why?
|
Proviruses | 9 | 2023 | 313 | 1.490 |
Why?
|
Infectious Disease Transmission, Vertical | 9 | 2023 | 1351 | 1.470 |
Why?
|
CD4 Lymphocyte Count | 29 | 2024 | 2571 | 1.340 |
Why?
|
Reverse Transcriptase Inhibitors | 8 | 2017 | 621 | 1.330 |
Why?
|
Medication Adherence | 6 | 2024 | 2176 | 1.250 |
Why?
|
Senegal | 31 | 2017 | 256 | 1.170 |
Why?
|
Selenium | 2 | 2021 | 417 | 1.110 |
Why?
|
HIV Seropositivity | 10 | 2017 | 960 | 1.100 |
Why?
|
Viral Nonstructural Proteins | 2 | 2018 | 227 | 1.090 |
Why?
|
Chikungunya virus | 2 | 2023 | 56 | 1.070 |
Why?
|
Ritonavir | 3 | 2021 | 329 | 1.040 |
Why?
|
Tuberculosis | 6 | 2021 | 2017 | 1.010 |
Why?
|
Nevirapine | 9 | 2016 | 273 | 0.930 |
Why?
|
Arboviruses | 1 | 2023 | 13 | 0.910 |
Why?
|
Enzyme-Linked Immunospot Assay | 3 | 2018 | 123 | 0.900 |
Why?
|
Arbovirus Infections | 1 | 2023 | 21 | 0.890 |
Why?
|
HIV | 15 | 2023 | 1582 | 0.880 |
Why?
|
Acquired Immunodeficiency Syndrome | 30 | 2011 | 2199 | 0.870 |
Why?
|
Freezing | 1 | 2024 | 311 | 0.860 |
Why?
|
RNA, Viral | 18 | 2017 | 2846 | 0.810 |
Why?
|
HIV Reverse Transcriptase | 6 | 2017 | 212 | 0.810 |
Why?
|
Zidovudine | 6 | 2017 | 624 | 0.800 |
Why?
|
HIV Antibodies | 17 | 2015 | 1303 | 0.760 |
Why?
|
HIV Seronegativity | 3 | 2017 | 211 | 0.730 |
Why?
|
Deltaretrovirus | 19 | 1988 | 162 | 0.720 |
Why?
|
Faculty | 2 | 2023 | 384 | 0.720 |
Why?
|
Rifabutin | 2 | 2021 | 59 | 0.710 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 7 | 2021 | 206 | 0.710 |
Why?
|
Reagent Kits, Diagnostic | 3 | 2018 | 239 | 0.700 |
Why?
|
Lost to Follow-Up | 4 | 2019 | 123 | 0.700 |
Why?
|
Phylogeny | 17 | 2021 | 2811 | 0.680 |
Why?
|
Genotype | 17 | 2021 | 12990 | 0.650 |
Why?
|
Pregnancy Outcome | 2 | 2021 | 2921 | 0.640 |
Why?
|
Antibiotics, Antitubercular | 1 | 2019 | 99 | 0.640 |
Why?
|
Mutation, Missense | 5 | 2019 | 2571 | 0.620 |
Why?
|
Female | 124 | 2024 | 392644 | 0.590 |
Why?
|
Publications | 1 | 2020 | 194 | 0.580 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2013 | 662 | 0.580 |
Why?
|
Adult | 84 | 2024 | 221177 | 0.580 |
Why?
|
Postpartum Period | 1 | 2024 | 1173 | 0.580 |
Why?
|
Point-of-Care Systems | 3 | 2023 | 1213 | 0.580 |
Why?
|
Poverty Areas | 1 | 2019 | 263 | 0.570 |
Why?
|
Trace Elements | 1 | 2019 | 195 | 0.570 |
Why?
|
HIV Protease | 4 | 2021 | 97 | 0.570 |
Why?
|
Disease Transmission, Infectious | 2 | 2015 | 559 | 0.560 |
Why?
|
Humans | 193 | 2024 | 761504 | 0.560 |
Why?
|
Efficiency | 1 | 2020 | 476 | 0.550 |
Why?
|
Cytidine Deaminase | 2 | 2008 | 243 | 0.540 |
Why?
|
DNA, Viral | 14 | 2019 | 2202 | 0.540 |
Why?
|
Antibodies, Viral | 21 | 2024 | 3156 | 0.530 |
Why?
|
Urban Population | 4 | 2019 | 2036 | 0.520 |
Why?
|
Chemoprevention | 2 | 2015 | 326 | 0.510 |
Why?
|
Ebolavirus | 1 | 2018 | 251 | 0.500 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2017 | 189 | 0.500 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 588 | 0.480 |
Why?
|
Sexually Transmitted Diseases | 3 | 2010 | 662 | 0.470 |
Why?
|
Treatment Failure | 9 | 2018 | 2645 | 0.470 |
Why?
|
Hot Flashes | 1 | 2017 | 330 | 0.460 |
Why?
|
Sputum | 2 | 2013 | 506 | 0.450 |
Why?
|
Molecular Sequence Data | 25 | 2013 | 17635 | 0.450 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2017 | 357 | 0.440 |
Why?
|
AIDS Serodiagnosis | 2 | 2014 | 220 | 0.430 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2018 | 420 | 0.420 |
Why?
|
Amodiaquine | 1 | 2013 | 58 | 0.420 |
Why?
|
Renal Insufficiency | 1 | 2019 | 809 | 0.420 |
Why?
|
T-Lymphocytes | 8 | 2018 | 10194 | 0.420 |
Why?
|
Antioxidants | 1 | 2021 | 1668 | 0.420 |
Why?
|
Health Education | 2 | 2014 | 1052 | 0.410 |
Why?
|
Male | 80 | 2023 | 360804 | 0.410 |
Why?
|
Hospital Information Systems | 1 | 2014 | 394 | 0.400 |
Why?
|
Prevalence | 18 | 2021 | 15732 | 0.380 |
Why?
|
Pregnancy | 20 | 2024 | 29874 | 0.380 |
Why?
|
Health Plan Implementation | 1 | 2014 | 337 | 0.380 |
Why?
|
Africa, Western | 11 | 2021 | 159 | 0.380 |
Why?
|
Young Adult | 21 | 2024 | 59243 | 0.370 |
Why?
|
HIV Seroprevalence | 6 | 2006 | 89 | 0.360 |
Why?
|
Retrospective Studies | 27 | 2024 | 80636 | 0.360 |
Why?
|
Peptide Hydrolases | 1 | 2013 | 624 | 0.350 |
Why?
|
Deltaretrovirus Infections | 6 | 1994 | 25 | 0.350 |
Why?
|
Counseling | 2 | 2010 | 1547 | 0.350 |
Why?
|
Condoms | 2 | 2010 | 331 | 0.350 |
Why?
|
Retroviridae | 15 | 1987 | 850 | 0.340 |
Why?
|
Adolescent | 22 | 2021 | 88319 | 0.320 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2013 | 1039 | 0.320 |
Why?
|
Universities | 3 | 2020 | 993 | 0.320 |
Why?
|
Menopause | 1 | 2017 | 1646 | 0.320 |
Why?
|
Cross-Sectional Studies | 19 | 2021 | 26125 | 0.320 |
Why?
|
HIV Antigens | 8 | 2002 | 325 | 0.320 |
Why?
|
HIV Envelope Protein gp120 | 7 | 2000 | 914 | 0.320 |
Why?
|
Hepatitis B, Chronic | 1 | 2013 | 410 | 0.310 |
Why?
|
Genes, Bacterial | 1 | 2012 | 1073 | 0.310 |
Why?
|
Cytosine Deaminase | 1 | 2008 | 66 | 0.310 |
Why?
|
Medical Records Systems, Computerized | 1 | 2014 | 1192 | 0.310 |
Why?
|
Pyridazines | 1 | 2010 | 202 | 0.310 |
Why?
|
Middle Aged | 41 | 2021 | 220895 | 0.300 |
Why?
|
Health Resources | 1 | 2014 | 935 | 0.300 |
Why?
|
Cross Reactions | 9 | 2024 | 817 | 0.300 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2019 | 4016 | 0.300 |
Why?
|
Hepatitis C, Chronic | 2 | 2013 | 1032 | 0.300 |
Why?
|
Genes, gag | 1 | 2007 | 55 | 0.290 |
Why?
|
Genes, env | 1 | 2007 | 95 | 0.290 |
Why?
|
Preventive Health Services | 1 | 2012 | 567 | 0.290 |
Why?
|
Patient Acceptance of Health Care | 4 | 2022 | 3205 | 0.290 |
Why?
|
Hepatitis C | 2 | 2008 | 1584 | 0.290 |
Why?
|
Molecular Epidemiology | 2 | 2007 | 469 | 0.290 |
Why?
|
Directly Observed Therapy | 1 | 2007 | 139 | 0.280 |
Why?
|
RNA-Directed DNA Polymerase | 4 | 2006 | 225 | 0.280 |
Why?
|
Health Services Research | 1 | 2015 | 1812 | 0.280 |
Why?
|
Truth Disclosure | 1 | 2011 | 434 | 0.280 |
Why?
|
Salvage Therapy | 1 | 2013 | 1264 | 0.280 |
Why?
|
Leukocytes, Mononuclear | 7 | 2023 | 1844 | 0.270 |
Why?
|
Gene Products, gag | 6 | 2005 | 312 | 0.270 |
Why?
|
Biomedical Research | 2 | 2020 | 3429 | 0.270 |
Why?
|
Sequence Analysis, DNA | 8 | 2019 | 4740 | 0.270 |
Why?
|
Gene Products, tat | 1 | 2006 | 111 | 0.270 |
Why?
|
Antimalarials | 1 | 2013 | 907 | 0.260 |
Why?
|
Sarcoma, Kaposi | 1 | 2009 | 374 | 0.260 |
Why?
|
Hepatitis B | 2 | 2009 | 705 | 0.260 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1265 | 0.260 |
Why?
|
Gene Products, env | 4 | 2007 | 250 | 0.250 |
Why?
|
Seroepidemiologic Studies | 3 | 2024 | 397 | 0.250 |
Why?
|
Cohort Studies | 26 | 2023 | 41487 | 0.240 |
Why?
|
Immunomagnetic Separation | 1 | 2005 | 79 | 0.240 |
Why?
|
Drug Resistance, Bacterial | 1 | 2012 | 1048 | 0.240 |
Why?
|
Virus Cultivation | 2 | 2024 | 88 | 0.240 |
Why?
|
Polymorphism, Genetic | 4 | 2008 | 4243 | 0.240 |
Why?
|
Mycobacterium tuberculosis | 2 | 2013 | 1914 | 0.240 |
Why?
|
Malaria, Falciparum | 1 | 2013 | 1077 | 0.230 |
Why?
|
Virus Integration | 1 | 2006 | 304 | 0.230 |
Why?
|
Flavivirus Infections | 1 | 2024 | 15 | 0.230 |
Why?
|
Flavivirus | 1 | 2024 | 22 | 0.230 |
Why?
|
Retroviridae Infections | 11 | 1995 | 147 | 0.230 |
Why?
|
Tuberculosis, Multidrug-Resistant | 1 | 2012 | 934 | 0.230 |
Why?
|
Infant | 10 | 2023 | 36192 | 0.230 |
Why?
|
Hospitals, Teaching | 5 | 2020 | 1156 | 0.230 |
Why?
|
Health Status | 2 | 2007 | 4077 | 0.220 |
Why?
|
Antitubercular Agents | 1 | 2012 | 1375 | 0.220 |
Why?
|
Prospective Studies | 17 | 2023 | 54425 | 0.220 |
Why?
|
Receptors, CCR5 | 3 | 2004 | 486 | 0.220 |
Why?
|
Recombination, Genetic | 6 | 2021 | 1519 | 0.220 |
Why?
|
Sensitivity and Specificity | 7 | 2022 | 14666 | 0.220 |
Why?
|
Point Mutation | 1 | 2008 | 1595 | 0.210 |
Why?
|
Cercopithecus | 6 | 1989 | 7 | 0.210 |
Why?
|
Patient Compliance | 3 | 2020 | 2690 | 0.210 |
Why?
|
Virus Replication | 6 | 2021 | 2435 | 0.210 |
Why?
|
Microbial Viability | 1 | 2024 | 238 | 0.210 |
Why?
|
Labor, Obstetric | 1 | 2006 | 323 | 0.210 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 2 | 2020 | 39 | 0.210 |
Why?
|
Polymerase Chain Reaction | 7 | 2022 | 6075 | 0.210 |
Why?
|
Amino Acid Sequence | 13 | 2008 | 13446 | 0.210 |
Why?
|
Infant, Newborn | 10 | 2023 | 26198 | 0.200 |
Why?
|
Evolution, Molecular | 3 | 2020 | 1886 | 0.200 |
Why?
|
Treatment Outcome | 13 | 2024 | 64680 | 0.200 |
Why?
|
Monkey Diseases | 10 | 1989 | 71 | 0.200 |
Why?
|
Pregnant Women | 2 | 2023 | 566 | 0.200 |
Why?
|
Immunoglobulin M | 2 | 2023 | 1527 | 0.200 |
Why?
|
Developing Countries | 4 | 2023 | 2885 | 0.190 |
Why?
|
Brazil | 2 | 2018 | 1230 | 0.190 |
Why?
|
Immunologic Tests | 1 | 2022 | 104 | 0.190 |
Why?
|
Disease Progression | 8 | 2021 | 13506 | 0.190 |
Why?
|
Limit of Detection | 1 | 2022 | 273 | 0.190 |
Why?
|
Genes, MHC Class I | 1 | 2002 | 235 | 0.190 |
Why?
|
Serologic Tests | 4 | 2022 | 381 | 0.190 |
Why?
|
Disclosure | 1 | 2006 | 748 | 0.180 |
Why?
|
Furin | 1 | 2020 | 46 | 0.180 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3889 | 0.180 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2023 | 4369 | 0.180 |
Why?
|
Longitudinal Studies | 8 | 2020 | 14605 | 0.180 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2020 | 71 | 0.180 |
Why?
|
Sequence Alignment | 4 | 2008 | 2180 | 0.170 |
Why?
|
Mothers | 2 | 2010 | 2198 | 0.170 |
Why?
|
Porins | 1 | 2000 | 78 | 0.170 |
Why?
|
Socioeconomic Factors | 6 | 2014 | 7827 | 0.170 |
Why?
|
Quality of Life | 3 | 2021 | 13367 | 0.170 |
Why?
|
Peptide Fragments | 5 | 2000 | 5112 | 0.160 |
Why?
|
Specimen Handling | 1 | 2024 | 702 | 0.160 |
Why?
|
Tumor Necrosis Factor-alpha | 4 | 2018 | 4352 | 0.160 |
Why?
|
Caregivers | 1 | 2011 | 2237 | 0.160 |
Why?
|
Cryopreservation | 1 | 2024 | 728 | 0.160 |
Why?
|
Congo | 1 | 2018 | 13 | 0.160 |
Why?
|
Vaginosis, Bacterial | 1 | 2000 | 151 | 0.160 |
Why?
|
Genital Diseases, Female | 1 | 2000 | 192 | 0.150 |
Why?
|
Africa | 6 | 2012 | 709 | 0.150 |
Why?
|
Viral Regulatory and Accessory Proteins | 1 | 1998 | 153 | 0.150 |
Why?
|
Genetic Variation | 4 | 2007 | 6567 | 0.150 |
Why?
|
Cleft Lip | 1 | 2023 | 506 | 0.150 |
Why?
|
Biometry | 1 | 2001 | 563 | 0.150 |
Why?
|
Chlamydia trachomatis | 1 | 2000 | 239 | 0.150 |
Why?
|
Base Sequence | 12 | 2004 | 12441 | 0.150 |
Why?
|
Cleft Palate | 1 | 2023 | 589 | 0.150 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 5 | 2010 | 3810 | 0.150 |
Why?
|
Mentors | 1 | 2023 | 661 | 0.150 |
Why?
|
DNA, Bacterial | 2 | 2013 | 1479 | 0.150 |
Why?
|
Adenine | 3 | 2013 | 987 | 0.150 |
Why?
|
Virus Activation | 1 | 2019 | 322 | 0.150 |
Why?
|
Genes, Viral | 8 | 2007 | 649 | 0.150 |
Why?
|
Mental Fatigue | 1 | 2017 | 23 | 0.140 |
Why?
|
Lamivudine | 5 | 2016 | 366 | 0.140 |
Why?
|
Parents | 1 | 2011 | 3563 | 0.140 |
Why?
|
RNA Helicases | 1 | 2018 | 144 | 0.140 |
Why?
|
Aged | 14 | 2021 | 169289 | 0.140 |
Why?
|
Population Surveillance | 1 | 2007 | 2598 | 0.140 |
Why?
|
Child | 9 | 2021 | 80153 | 0.140 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2000 | 406 | 0.140 |
Why?
|
Glomerular Filtration Rate | 2 | 2019 | 2176 | 0.140 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2020 | 629 | 0.140 |
Why?
|
Amino Acid Substitution | 3 | 2010 | 1738 | 0.140 |
Why?
|
Bronchi | 1 | 2020 | 845 | 0.140 |
Why?
|
Serine Endopeptidases | 2 | 2020 | 1022 | 0.140 |
Why?
|
Interleukin-1 | 1 | 2000 | 1248 | 0.140 |
Why?
|
Antigens, Bacterial | 2 | 2018 | 1155 | 0.130 |
Why?
|
Occupations | 1 | 2019 | 515 | 0.130 |
Why?
|
Bacterial Toxins | 2 | 2018 | 931 | 0.130 |
Why?
|
Chlamydia Infections | 1 | 2000 | 365 | 0.130 |
Why?
|
Neonatal Screening | 1 | 2020 | 597 | 0.130 |
Why?
|
RNA, Messenger | 3 | 2020 | 12795 | 0.130 |
Why?
|
Antigens, Viral | 10 | 1988 | 988 | 0.130 |
Why?
|
Education, Medical | 2 | 2020 | 1725 | 0.130 |
Why?
|
Viremia | 3 | 2008 | 707 | 0.130 |
Why?
|
Double-Blind Method | 2 | 2021 | 12341 | 0.130 |
Why?
|
Simian immunodeficiency virus | 5 | 1997 | 809 | 0.120 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 4575 | 0.120 |
Why?
|
Drug Interactions | 1 | 2019 | 1416 | 0.120 |
Why?
|
Mutation | 6 | 2020 | 30052 | 0.120 |
Why?
|
Stavudine | 3 | 2013 | 85 | 0.120 |
Why?
|
Time Factors | 10 | 2019 | 39967 | 0.120 |
Why?
|
Demography | 4 | 2020 | 1648 | 0.120 |
Why?
|
Placebos | 1 | 2019 | 1667 | 0.120 |
Why?
|
Peer Group | 1 | 2000 | 692 | 0.120 |
Why?
|
Flow Cytometry | 1 | 2005 | 5869 | 0.120 |
Why?
|
Risk Factors | 14 | 2015 | 74206 | 0.110 |
Why?
|
RNA | 1 | 2023 | 2726 | 0.110 |
Why?
|
World Health Organization | 3 | 2017 | 1322 | 0.110 |
Why?
|
Immunoenzyme Techniques | 3 | 2001 | 1705 | 0.110 |
Why?
|
Hepatitis C Antibodies | 1 | 2013 | 146 | 0.110 |
Why?
|
Hospitals, University | 1 | 2015 | 563 | 0.110 |
Why?
|
Alkynes | 4 | 2016 | 320 | 0.100 |
Why?
|
Birth Weight | 1 | 2021 | 2103 | 0.100 |
Why?
|
Retroviruses, Simian | 2 | 1989 | 12 | 0.100 |
Why?
|
Cyclopropanes | 4 | 2016 | 432 | 0.100 |
Why?
|
Immunoglobulin G | 3 | 2018 | 4544 | 0.100 |
Why?
|
Logistic Models | 3 | 2017 | 13255 | 0.100 |
Why?
|
Anemia, Sickle Cell | 1 | 2020 | 1063 | 0.100 |
Why?
|
Benzoxazines | 4 | 2016 | 316 | 0.100 |
Why?
|
Drug Substitution | 1 | 2015 | 290 | 0.100 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2013 | 294 | 0.100 |
Why?
|
Cluster Analysis | 2 | 2020 | 2707 | 0.090 |
Why?
|
Alleles | 2 | 2002 | 6863 | 0.090 |
Why?
|
Educational Status | 1 | 2019 | 2522 | 0.090 |
Why?
|
Africa South of the Sahara | 3 | 2022 | 744 | 0.090 |
Why?
|
Incidence | 6 | 2021 | 21353 | 0.090 |
Why?
|
Viral Proteins | 6 | 2010 | 1804 | 0.090 |
Why?
|
Species Specificity | 5 | 2006 | 2414 | 0.090 |
Why?
|
Macaca | 5 | 1985 | 410 | 0.090 |
Why?
|
Health Services Accessibility | 2 | 2021 | 5440 | 0.090 |
Why?
|
Genome, Viral | 2 | 2004 | 667 | 0.090 |
Why?
|
Risk | 2 | 2001 | 9610 | 0.090 |
Why?
|
Age Factors | 3 | 2019 | 18395 | 0.090 |
Why?
|
Pathology, Molecular | 1 | 2013 | 328 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2018 | 3162 | 0.090 |
Why?
|
Homosexuality, Male | 2 | 2022 | 1334 | 0.080 |
Why?
|
Peptide Biosynthesis | 1 | 2009 | 52 | 0.080 |
Why?
|
Lymphoma | 7 | 1996 | 1901 | 0.080 |
Why?
|
Risk Assessment | 2 | 2019 | 23995 | 0.080 |
Why?
|
AIDS Vaccines | 3 | 2000 | 896 | 0.080 |
Why?
|
Data Collection | 2 | 2014 | 3322 | 0.080 |
Why?
|
Alanine Transaminase | 2 | 2013 | 603 | 0.080 |
Why?
|
Human Rights | 1 | 2012 | 309 | 0.080 |
Why?
|
vif Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 53 | 0.080 |
Why?
|
Haplorhini | 6 | 1988 | 525 | 0.080 |
Why?
|
Premature Birth | 1 | 2021 | 1782 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 6484 | 0.080 |
Why?
|
Echocardiography | 1 | 2021 | 4989 | 0.080 |
Why?
|
HLA-DR Antigens | 2 | 2007 | 602 | 0.070 |
Why?
|
5' Untranslated Regions | 1 | 2009 | 256 | 0.070 |
Why?
|
Maternal Health Services | 2 | 2021 | 461 | 0.070 |
Why?
|
International Cooperation | 1 | 2014 | 1422 | 0.070 |
Why?
|
Microscopy | 1 | 2013 | 903 | 0.070 |
Why?
|
Gene Frequency | 2 | 2007 | 3606 | 0.070 |
Why?
|
Health Personnel | 1 | 2021 | 3335 | 0.070 |
Why?
|
Education | 1 | 2010 | 537 | 0.070 |
Why?
|
Malaria | 1 | 2017 | 1227 | 0.070 |
Why?
|
Program Evaluation | 2 | 2010 | 2495 | 0.070 |
Why?
|
Aged, 80 and over | 3 | 2019 | 58976 | 0.070 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2012 | 611 | 0.070 |
Why?
|
Fluorescent Antibody Technique, Direct | 1 | 2007 | 66 | 0.070 |
Why?
|
Dyslipidemias | 1 | 2014 | 868 | 0.070 |
Why?
|
Papillomaviridae | 1 | 2013 | 1119 | 0.070 |
Why?
|
Portugal | 1 | 2006 | 91 | 0.070 |
Why?
|
Health Surveys | 1 | 2017 | 4061 | 0.070 |
Why?
|
Viral Envelope Proteins | 5 | 2000 | 640 | 0.070 |
Why?
|
Genes, pol | 1 | 2006 | 52 | 0.070 |
Why?
|
HLA-C Antigens | 1 | 2007 | 140 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3416 | 0.070 |
Why?
|
HLA-A Antigens | 1 | 2007 | 223 | 0.070 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1386 | 0.070 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 119 | 0.070 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2013 | 832 | 0.070 |
Why?
|
Base Composition | 1 | 2006 | 290 | 0.070 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 1988 | 899 | 0.070 |
Why?
|
Prenatal Care | 1 | 2013 | 1139 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 4 | 2001 | 1784 | 0.060 |
Why?
|
HLA-B Antigens | 1 | 2007 | 317 | 0.060 |
Why?
|
Immunoblotting | 2 | 2000 | 1646 | 0.060 |
Why?
|
India | 1 | 2012 | 2348 | 0.060 |
Why?
|
Politics | 1 | 2012 | 815 | 0.060 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 1 | 2008 | 369 | 0.060 |
Why?
|
Drug Monitoring | 1 | 2011 | 962 | 0.060 |
Why?
|
DNA Primers | 4 | 1999 | 2819 | 0.060 |
Why?
|
Spain | 1 | 2006 | 487 | 0.060 |
Why?
|
Sexual Partners | 1 | 2010 | 796 | 0.060 |
Why?
|
Survival Analysis | 2 | 2009 | 10090 | 0.060 |
Why?
|
Neutralization Tests | 1 | 2007 | 728 | 0.060 |
Why?
|
Ferrets | 2 | 1996 | 177 | 0.060 |
Why?
|
Receptors, Virus | 1 | 1988 | 640 | 0.060 |
Why?
|
Nitriles | 1 | 2010 | 971 | 0.060 |
Why?
|
RNA Splicing | 1 | 2009 | 918 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39106 | 0.060 |
Why?
|
Chromosomes, Human | 1 | 2006 | 441 | 0.060 |
Why?
|
Yellow fever virus | 1 | 2024 | 23 | 0.060 |
Why?
|
Heart Defects, Congenital | 1 | 2021 | 4671 | 0.060 |
Why?
|
Heterochromatin | 1 | 2006 | 293 | 0.060 |
Why?
|
Random Allocation | 1 | 2018 | 2395 | 0.060 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1787 | 0.060 |
Why?
|
Plasma | 1 | 2007 | 586 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2018 | 12974 | 0.050 |
Why?
|
Chemokines, CC | 2 | 2004 | 283 | 0.050 |
Why?
|
Child, Preschool | 2 | 2017 | 42230 | 0.050 |
Why?
|
Adiponectin | 2 | 2006 | 1113 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2013 | 12463 | 0.050 |
Why?
|
Animals | 33 | 2024 | 168459 | 0.050 |
Why?
|
Drug Therapy, Combination | 5 | 2013 | 6310 | 0.050 |
Why?
|
HLA-B35 Antigen | 1 | 2002 | 7 | 0.050 |
Why?
|
Simian T-lymphotropic virus 1 | 2 | 1994 | 6 | 0.050 |
Why?
|
Comorbidity | 1 | 2017 | 10508 | 0.050 |
Why?
|
Automation | 1 | 2005 | 586 | 0.050 |
Why?
|
Consensus Sequence | 1 | 2002 | 365 | 0.050 |
Why?
|
Anxiety | 1 | 2017 | 4573 | 0.050 |
Why?
|
Religion | 1 | 2005 | 372 | 0.050 |
Why?
|
Immunocompromised Host | 1 | 2007 | 856 | 0.050 |
Why?
|
Pain | 1 | 2017 | 5073 | 0.050 |
Why?
|
Sequence Homology, Amino Acid | 2 | 1996 | 2748 | 0.050 |
Why?
|
Africa, Eastern | 1 | 2021 | 76 | 0.050 |
Why?
|
Tetanus Toxoid | 1 | 2001 | 189 | 0.050 |
Why?
|
Burkina Faso | 1 | 2021 | 86 | 0.050 |
Why?
|
Antirheumatic Agents | 1 | 2011 | 1372 | 0.050 |
Why?
|
Papillomavirus Infections | 1 | 2013 | 1613 | 0.050 |
Why?
|
Virulence | 2 | 2003 | 1303 | 0.050 |
Why?
|
Survival Rate | 2 | 2009 | 12725 | 0.040 |
Why?
|
Stillbirth | 1 | 2023 | 368 | 0.040 |
Why?
|
Sexual Behavior | 1 | 2010 | 2180 | 0.040 |
Why?
|
Uterine Cervicitis | 1 | 2000 | 31 | 0.040 |
Why?
|
Phylogeography | 1 | 2020 | 72 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 1 | 2002 | 17904 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2013 | 5492 | 0.040 |
Why?
|
Blotting, Southern | 2 | 1998 | 777 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2005 | 2927 | 0.040 |
Why?
|
Mass Screening | 2 | 2013 | 5428 | 0.040 |
Why?
|
Ethiopia | 1 | 2021 | 464 | 0.040 |
Why?
|
Quality of Health Care | 1 | 2014 | 4330 | 0.040 |
Why?
|
Adipocytes | 1 | 2006 | 1194 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15842 | 0.040 |
Why?
|
Stroke | 1 | 2021 | 9757 | 0.040 |
Why?
|
Deoxycytidine | 2 | 2013 | 877 | 0.040 |
Why?
|
Immunoassay | 2 | 2000 | 745 | 0.040 |
Why?
|
Telephone | 1 | 2021 | 627 | 0.040 |
Why?
|
Pyrimidines | 1 | 2010 | 3028 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2000 | 1624 | 0.040 |
Why?
|
Binding Sites | 1 | 2006 | 6055 | 0.040 |
Why?
|
Amino Acid Motifs | 1 | 2000 | 931 | 0.040 |
Why?
|
Cytopathogenic Effect, Viral | 2 | 1988 | 151 | 0.040 |
Why?
|
Botswana | 1 | 2020 | 1048 | 0.040 |
Why?
|
Retroviridae Proteins | 2 | 1987 | 94 | 0.040 |
Why?
|
Depression | 1 | 2017 | 8124 | 0.040 |
Why?
|
Sex Factors | 1 | 2011 | 10552 | 0.040 |
Why?
|
HIV Core Protein p24 | 2 | 1997 | 245 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 2 | 2001 | 974 | 0.040 |
Why?
|
Prognosis | 3 | 2021 | 29625 | 0.030 |
Why?
|
Down-Regulation | 1 | 2004 | 2919 | 0.030 |
Why?
|
Virus Internalization | 1 | 2020 | 497 | 0.030 |
Why?
|
Papio | 3 | 1988 | 669 | 0.030 |
Why?
|
Cervix Uteri | 1 | 2000 | 570 | 0.030 |
Why?
|
Urban Health Services | 1 | 1997 | 177 | 0.030 |
Why?
|
Blotting, Western | 4 | 1998 | 5035 | 0.030 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2003 | 1651 | 0.030 |
Why?
|
Child Health Services | 1 | 2021 | 646 | 0.030 |
Why?
|
Social Stigma | 1 | 2022 | 769 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2019 | 617 | 0.030 |
Why?
|
Gene Amplification | 1 | 1999 | 1089 | 0.030 |
Why?
|
Adipose Tissue | 2 | 2006 | 3312 | 0.030 |
Why?
|
Urban Health | 1 | 1997 | 532 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2005 | 4580 | 0.030 |
Why?
|
Uganda | 1 | 1999 | 1332 | 0.030 |
Why?
|
Human T-lymphotropic virus 2 | 1 | 1994 | 10 | 0.030 |
Why?
|
Cebidae | 1 | 1994 | 21 | 0.030 |
Why?
|
Pilot Projects | 2 | 2020 | 8631 | 0.030 |
Why?
|
Disease Reservoirs | 1 | 1994 | 121 | 0.030 |
Why?
|
Body Composition | 1 | 2003 | 2426 | 0.030 |
Why?
|
Genome, Human | 1 | 2006 | 4425 | 0.030 |
Why?
|
Databases, Genetic | 1 | 2020 | 1742 | 0.030 |
Why?
|
Microscopy, Electron | 2 | 1986 | 2561 | 0.030 |
Why?
|
Organophosphorus Compounds | 1 | 2013 | 206 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2020 | 2330 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2019 | 2696 | 0.020 |
Why?
|
Democratic Republic of the Congo | 2 | 1993 | 86 | 0.020 |
Why?
|
Multivariate Analysis | 2 | 1997 | 12059 | 0.020 |
Why?
|
Macaca mulatta | 4 | 1985 | 2329 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 1997 | 935 | 0.020 |
Why?
|
Antigen-Antibody Complex | 1 | 1993 | 510 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 15936 | 0.020 |
Why?
|
Burundi | 2 | 1987 | 12 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2013 | 499 | 0.020 |
Why?
|
Hepatitis, Viral, Animal | 1 | 1989 | 10 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 1998 | 3734 | 0.020 |
Why?
|
Brain | 1 | 1996 | 27112 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5247 | 0.020 |
Why?
|
Lymphocytes | 2 | 1989 | 2612 | 0.020 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 384 | 0.020 |
Why?
|
Hepatitis B e Antigens | 1 | 2009 | 133 | 0.020 |
Why?
|
Molecular Weight | 3 | 1987 | 2186 | 0.020 |
Why?
|
Reference Values | 2 | 2005 | 4920 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2020 | 3673 | 0.020 |
Why?
|
HLA-D Antigens | 1 | 1988 | 129 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2020 | 18965 | 0.020 |
Why?
|
Epitope Mapping | 2 | 2000 | 298 | 0.020 |
Why?
|
Proteins | 1 | 2003 | 6032 | 0.020 |
Why?
|
Cell Fusion | 1 | 1988 | 294 | 0.020 |
Why?
|
Gene Expression | 1 | 2020 | 7581 | 0.020 |
Why?
|
Forecasting | 1 | 1997 | 2928 | 0.020 |
Why?
|
Luciferases | 1 | 2009 | 714 | 0.020 |
Why?
|
Lymphocyte Activation | 3 | 2005 | 5486 | 0.020 |
Why?
|
Cuba | 1 | 2007 | 48 | 0.020 |
Why?
|
Africa, Central | 1 | 1987 | 8 | 0.020 |
Why?
|
Endonucleases | 2 | 1987 | 371 | 0.020 |
Why?
|
COS Cells | 1 | 2009 | 1130 | 0.020 |
Why?
|
Genes | 2 | 1988 | 1823 | 0.020 |
Why?
|
Hemophilia A | 3 | 1985 | 360 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2014 | 1505 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2002 | 22176 | 0.020 |
Why?
|
Cameroon | 1 | 1987 | 76 | 0.020 |
Why?
|
Odds Ratio | 2 | 2005 | 9646 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 2 | 1986 | 1741 | 0.020 |
Why?
|
Drug Combinations | 1 | 2013 | 2048 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2005 | 20098 | 0.020 |
Why?
|
Genes, Regulator | 1 | 1987 | 373 | 0.020 |
Why?
|
Zambia | 1 | 1987 | 262 | 0.020 |
Why?
|
Italy | 1 | 1988 | 842 | 0.020 |
Why?
|
Macaca fascicularis | 2 | 1985 | 903 | 0.020 |
Why?
|
Zoonoses | 1 | 1987 | 179 | 0.020 |
Why?
|
Animals, Wild | 1 | 1985 | 78 | 0.020 |
Why?
|
Hepacivirus | 1 | 2013 | 1336 | 0.020 |
Why?
|
Receptors, HIV | 1 | 2006 | 159 | 0.020 |
Why?
|
Transcription, Genetic | 1 | 1999 | 7594 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1899 | 0.020 |
Why?
|
Niger | 1 | 2005 | 38 | 0.020 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2006 | 138 | 0.020 |
Why?
|
United States | 6 | 2004 | 72334 | 0.020 |
Why?
|
Models, Biological | 1 | 2020 | 9469 | 0.010 |
Why?
|
Kenya | 1 | 1987 | 758 | 0.010 |
Why?
|
Prisoners | 1 | 1987 | 314 | 0.010 |
Why?
|
Viruses | 1 | 1987 | 375 | 0.010 |
Why?
|
Adipogenesis | 1 | 2006 | 368 | 0.010 |
Why?
|
Government Programs | 1 | 2005 | 279 | 0.010 |
Why?
|
Marriage | 1 | 2005 | 351 | 0.010 |
Why?
|
Academies and Institutes | 1 | 2005 | 318 | 0.010 |
Why?
|
Antibody Specificity | 1 | 1985 | 1060 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2020 | 11528 | 0.010 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 1987 | 547 | 0.010 |
Why?
|
Regression Analysis | 1 | 1992 | 6343 | 0.010 |
Why?
|
Biological Evolution | 1 | 1988 | 1071 | 0.010 |
Why?
|
Tanzania | 1 | 1987 | 1387 | 0.010 |
Why?
|
Leukemia Virus, Feline | 2 | 1996 | 5 | 0.010 |
Why?
|
DNA Helicases | 1 | 1987 | 851 | 0.010 |
Why?
|
Monitoring, Immunologic | 1 | 2001 | 98 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2013 | 2020 | 0.010 |
Why?
|
Immune Tolerance | 2 | 1994 | 2303 | 0.010 |
Why?
|
Exanthema | 1 | 2005 | 503 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8654 | 0.010 |
Why?
|
Fluorescent Antibody Technique | 1 | 1985 | 2469 | 0.010 |
Why?
|
Glucose Tolerance Test | 1 | 2003 | 1178 | 0.010 |
Why?
|
Cell Line | 3 | 1988 | 15601 | 0.010 |
Why?
|
Anemia | 1 | 1989 | 1509 | 0.010 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 1994 | 1058 | 0.010 |
Why?
|
Immunization, Secondary | 1 | 2001 | 367 | 0.010 |
Why?
|
Interleukin-2 | 1 | 2006 | 1889 | 0.010 |
Why?
|
Indinavir | 1 | 1998 | 73 | 0.010 |
Why?
|
Serotyping | 1 | 1999 | 325 | 0.010 |
Why?
|
Lipoproteins, HDL | 1 | 2003 | 676 | 0.010 |
Why?
|
Gene Products, pol | 1 | 1997 | 43 | 0.010 |
Why?
|
Tissue Donors | 1 | 1987 | 2331 | 0.010 |
Why?
|
Gene Products, nef | 1 | 1997 | 100 | 0.010 |
Why?
|
Escherichia coli | 1 | 1990 | 4217 | 0.010 |
Why?
|
Databases, Factual | 1 | 2013 | 7967 | 0.010 |
Why?
|
Leukocyte Count | 2 | 1994 | 1596 | 0.010 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 1997 | 148 | 0.010 |
Why?
|
Glycoproteins | 1 | 1985 | 2203 | 0.010 |
Why?
|
Administration, Oral | 1 | 2005 | 4021 | 0.010 |
Why?
|
Cloning, Molecular | 3 | 1987 | 4174 | 0.010 |
Why?
|
Absorptiometry, Photon | 1 | 2003 | 1738 | 0.010 |
Why?
|
Aleutian Mink Disease Virus | 1 | 1996 | 1 | 0.010 |
Why?
|
HIV Protease Inhibitors | 1 | 1998 | 432 | 0.010 |
Why?
|
Primates | 2 | 1991 | 523 | 0.010 |
Why?
|
Massachusetts | 1 | 1989 | 8830 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2006 | 3208 | 0.010 |
Why?
|
Antigen Presentation | 1 | 2001 | 1251 | 0.010 |
Why?
|
HIV Envelope Protein gp41 | 1 | 1997 | 303 | 0.010 |
Why?
|
Antibodies, Bacterial | 1 | 2001 | 1469 | 0.010 |
Why?
|
Inpatients | 1 | 1987 | 2548 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2011 | 15266 | 0.010 |
Why?
|
Cell Transformation, Viral | 2 | 1987 | 526 | 0.010 |
Why?
|
Integrases | 2 | 1987 | 516 | 0.010 |
Why?
|
Genes, pX | 1 | 1994 | 7 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 2001 | 1802 | 0.010 |
Why?
|
DNA Probes | 1 | 1994 | 541 | 0.010 |
Why?
|
Genetics, Population | 1 | 1997 | 937 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2009 | 16981 | 0.010 |
Why?
|
Recombinant Proteins | 2 | 1994 | 6534 | 0.010 |
Why?
|
HLA Antigens | 1 | 1997 | 1328 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2005 | 4028 | 0.010 |
Why?
|
beta 2-Microglobulin | 1 | 1993 | 329 | 0.010 |
Why?
|
Homeostasis | 1 | 2003 | 3323 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 1997 | 1560 | 0.010 |
Why?
|
Mathematics | 1 | 1993 | 707 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 1988 | 9177 | 0.010 |
Why?
|
Neoplasm Transplantation | 1 | 1995 | 2016 | 0.010 |
Why?
|
Gene Expression Regulation | 2 | 2004 | 11903 | 0.010 |
Why?
|
Cytokines | 1 | 2004 | 7396 | 0.010 |
Why?
|
Lentivirus | 1 | 1991 | 508 | 0.000 |
Why?
|
Insulin | 1 | 2003 | 6596 | 0.000 |
Why?
|
Paramyxoviridae | 1 | 1987 | 9 | 0.000 |
Why?
|
Travel | 1 | 1993 | 796 | 0.000 |
Why?
|
Probability | 1 | 1993 | 2477 | 0.000 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 1 | 1991 | 541 | 0.000 |
Why?
|
AIDS-Related Complex | 1 | 1987 | 107 | 0.000 |
Why?
|
Herpesviridae | 1 | 1987 | 106 | 0.000 |
Why?
|
Viral Core Proteins | 1 | 1987 | 161 | 0.000 |
Why?
|
DNA Nucleotidyltransferases | 1 | 1987 | 175 | 0.000 |
Why?
|
Leukemia | 2 | 1985 | 1522 | 0.000 |
Why?
|
DNA Restriction Enzymes | 1 | 1987 | 550 | 0.000 |
Why?
|
Codon | 1 | 1988 | 601 | 0.000 |
Why?
|
Rotavirus | 1 | 1987 | 109 | 0.000 |
Why?
|
Orthomyxoviridae | 1 | 1987 | 149 | 0.000 |
Why?
|
Disease Outbreaks | 1 | 1996 | 1749 | 0.000 |
Why?
|
Immunoglobulins | 1 | 1989 | 853 | 0.000 |
Why?
|
Cat Diseases | 1 | 1985 | 31 | 0.000 |
Why?
|
Apoptosis | 1 | 2001 | 9486 | 0.000 |
Why?
|
Nucleic Acid Hybridization | 1 | 1987 | 1302 | 0.000 |
Why?
|
Body Mass Index | 1 | 2003 | 12953 | 0.000 |
Why?
|
Epitopes | 1 | 1991 | 2503 | 0.000 |
Why?
|
Cats | 1 | 1985 | 975 | 0.000 |
Why?
|
Repetitive Sequences, Nucleic Acid | 1 | 1985 | 783 | 0.000 |
Why?
|
Rural Population | 1 | 1993 | 2285 | 0.000 |
Why?
|
Carrier State | 1 | 1985 | 523 | 0.000 |
Why?
|
Antibody Formation | 1 | 1985 | 1395 | 0.000 |
Why?
|
Lymphoproliferative Disorders | 1 | 1984 | 531 | 0.000 |
Why?
|
Japan | 1 | 1985 | 1378 | 0.000 |
Why?
|
Oncogenes | 1 | 1985 | 1222 | 0.000 |
Why?
|
Peptides | 1 | 1991 | 4358 | 0.000 |
Why?
|
Mice | 1 | 2006 | 81525 | 0.000 |
Why?
|
Blood Transfusion | 1 | 1985 | 1298 | 0.000 |
Why?
|
Models, Statistical | 1 | 1993 | 5079 | 0.000 |
Why?
|
Immunohistochemistry | 1 | 1989 | 11076 | 0.000 |
Why?
|
Aging | 1 | 1988 | 8708 | 0.000 |
Why?
|